Stimulation of the mast cell IgE-receptor (FcεRI) by antigen leads to stimulation of Ca2+ entry with subsequent mast cell degranulation and release of inflammatory mediators. Ca2+ further activates Ca2+-activated K+ channels, which in turn provide the electrical driving force for Ca2+ entry. Since phosphatidylinositol (PI)-3-kinase has previously been shown to be required for mast cell activation and degranulation, we explored, whether mast cell Ca2+ and Ca2+-activated K+ channels may be sensitive to PI3-kinase activity. Whole-cell patch clamp experiments and Fura-2 fluorescence measurements for determination of cytosolic Ca2+ concentration were performed in mouse bone marrow-derived mast cells either treated or untreated with the PI3-kinase inhibitors LY-294002 (10 µM) and wortmannin (100 nM). Antigen-stimulated Ca2+ entry but not Ca2+ release from the intracellular stores was dramatically reduced upon PI3-kinase inhibition. Ca2+ entry was further inhibited by TRPV blocker ruthenium red (10 µM). Ca2+ entry following readdition after Ca+-store depletion with thapsigargin was again decreased by LY-294002, pointing to inhibition of store-operated channels (SOCs). Moreover, inhibition of PI3-kinase abrogated IgE-stimulated, but not ionomycin-induced stimulation of Ca2+-activated K+ channels. These observations disclose PI3-kinase-dependent regulation of Ca2+ entry and Ca2+-activated K+-channels, which in turn participate in triggering mast cell degranulation.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.